Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
BBOT
BridgeBio Oncology Therapeutics, Inc.
CAPPED RATING
BridgeBio Oncology Therapeutics, Inc. (BBOT) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
2.1
/ 5.0
C-
Value
B+
Factor Score
3.7
/ 5.0
Growth
C-
Factor Score
1.9
/ 5.0
Profitability
C-
Factor Score
2.0
/ 5.0
Momentum
F
Factor Score
0.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
4.0
EV / EBITDA
0.2
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-77.9%
Price Return 12M
-84.0%
Catalyst Signal
0.00
Market Cap
$158.9M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-46.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B+ (3.7) | C- (1.9) | C- (2.0) | F (0.5) | C+ (2.6) | C- (2.1) |
| 2026-11-10 | A- (3.9) | C- (1.9) | C (2.2) | F (0.6) | C+ (2.6) | C (2.2) |
| 2026-11-03 | B+ (3.7) | D+ (1.8) | C (2.2) | F (0.7) | C+ (2.7) | C (2.2) |
| 2026-10-27 | B+ (3.7) | D+ (1.8) | C (2.4) | F (0.7) | C+ (2.6) | C (2.2) |
| 2026-10-20 | C+ (2.5) | D+ (1.8) | C (2.4) | D- (0.8) | C+ (2.6) | C- (2.0) |
Page
1
of
4